Agilent Technologies Completes Acquisition of Seahorse Bioscience, Industry Leader in Tools for Measuring Cell Metabolism

SANTA CLARA, Calif., Nov. 2, 2015

Agilent Technologies Inc. today announced it has completed the acquisition of Seahorse Bioscience, a leader in providing instruments and assay kits for measuring cell metabolism and bioenergetics. Agilent announced its intent to acquire Seahorse on Sept. 9.

Seahorse's leading technology enables researchers to better understand cell health, function and signaling, and how the cell may be impacted by the introduction of a specific drug, by providing real-time kinetics to unlock essential cellular bioenergetics data.

Agilent acquired Seahorse Bioscience because its unique technology complements Agilent's leading separations and mass spectrometry solutions, in particular for metabolomics and disease research in pharma.

Scientists use Seahorse Bioscience's proprietary XF Technology to research the role of cell metabolism in neurodegeneration, aging, cancer, cardiovascular disease, cell physiology, toxicology and hepatobiology, immunology, infectious diseases, mitochondrial diseases, model organisms, obesity, diabetes, metabolic disorders, screening and translational medicine.

With the completion of the acquisition, most of the 200 employees who were with Seahorse are now part of the Mass Spectrometry Division of Agilent's Life Sciences and Applied Markets Group.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A), a global leader in life sciences, diagnostics and applied chemical markets, is the premier laboratory partner for a better world. Agilent works with customers in more than 100 countries, providing instruments, software, services and consumables for the entire laboratory workflow. The company generated revenues of $4.0 billion in fiscal 2014 and employs about 12,000 people worldwide. Agilent marks its 50th anniversary in analytical instrumentation this year. Information about Agilent is available at

# # #


Michele Drake, Corporate
+1 408 345 8396

Victoria Wadsworth-Hansen, Business
+1 408 553 2005

Investor Contact:

Alicia Rodriguez, Agilent
+1 408 345 8948